About Icon (NASDAQ:ICLR)
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio21.34
Forward P/E Ratio21.24
Sales & Book Value
Annual Sales$1.67 billion
Price / Sales3.70
Cash Flow$6.17 per share
Price / Cash18.47
Book Value$17.33 per share
Price / Book6.57
Net Income$262.17 million
Return on Equity28.42%
Return on Assets15.06%
Icon (NASDAQ:ICLR) Frequently Asked Questions
What is Icon's stock symbol?
Icon trades on the NASDAQ under the ticker symbol "ICLR."
How were Icon's earnings last quarter?
Icon Plc (NASDAQ:ICLR) released its quarterly earnings results on Thursday, October, 26th. The medical research company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.32 by $0.03. The medical research company earned $440.30 million during the quarter, compared to analyst estimates of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company's quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.19 earnings per share. View Icon's Earnings History.
When will Icon make its next earnings announcement?
What guidance has Icon issued on next quarter's earnings?
Icon issued an update on its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share (EPS) guidance of $5.30-5.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.37. The company issued revenue guidance of $1.74-1.77 billion, compared to the consensus revenue estimate of $1.76 billion.
Where is Icon's stock going? Where will Icon's stock price be in 2017?
10 analysts have issued 12-month price targets for Icon's stock. Their forecasts range from $92.00 to $138.00. On average, they expect Icon's stock price to reach $120.30 in the next year. View Analyst Ratings for Icon.
Are investors shorting Icon?
Icon saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 423,883 shares, a decrease of 47.8% from the October 31st total of 812,161 shares. Based on an average trading volume of 302,426 shares, the days-to-cover ratio is currently 1.4 days. Approximately 0.8% of the shares of the company are short sold.
Who are some of Icon's key competitors?
Some companies that are related to Icon include Nektar Therapeutics (NKTR), Alkermes (ALKS), Seattle Genetics (SGEN), Qiagen (QGEN), Sage Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), EXACT Sciences (EXAS), United Therapeutics (UTHR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), BIO-TECHNE (TECH), Galapagos (GLPG), Anacor Pharmaceuticals (ANAC), INC Research (INCR), Puma Biotechnology (PBYI), FibroGen (FGEN), ACADIA Pharmaceuticals (ACAD) and Blueprint Medicines (BPMC).
Who are Icon's key executives?
Icon's management team includes the folowing people:
- Ciaran Murray, Chairman of the Board (Age 53)
- Steve Cutler, Chief Executive Officer, Director (Age 54)
- Brendan Brennan, Chief Financial Officer (Age 36)
- Diarmaid Cunningham, Executive Vice President, General Counsel, Secretary (Age 40)
- Hugh Brady, Non-Executive Director (Age 57)
- John Climax, Non-Executive Director (Age 62)
- Joan Garahy, Non-Executive Director (Age 54)
- William W. Hall M.D., Ph.D., Non-Executive Director (Age 65)
- Ronan Lambe Ph.D., Non-Executive Director (Age 75)
Who owns Icon stock?
Icon's stock is owned by many different of institutional and retail investors. Top institutional investors include WCM Investment Management CA (7.47%),
EARNEST PARTNERS LLC
(4.90%), Earnest Partners LLC (4.85%), Wasatch Advisors Inc. (3.37%), Neuberger Berman Group LLC (2.37%) and Boston Partners (2.05%). View Institutional Ownership Trends for Icon.
Who sold Icon stock? Who is selling Icon stock?
Icon's stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Macquarie Group Ltd., Earnest Partners LLC, Boston Partners, Janus Henderson Group PLC, Systematic Financial Management LP, Pax World Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Icon.
Who bought Icon stock? Who is buying Icon stock?
Icon's stock was acquired by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Ameriprise Financial Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc., WCM Investment Management CA, Comgest Global Investors S.A.S., Tygh Capital Management Inc. and Chartwell Investment Partners LLC. View Insider Buying and Selling for Icon.
How do I buy Icon stock?
Shares of Icon can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Icon's stock price today?
One share of Icon stock can currently be purchased for approximately $113.87.
How big of a company is Icon?
Icon has a market capitalization of $6.02 billion and generates $1.67 billion in revenue each year. The medical research company earns $262.17 million in net income (profit) each year or $5.16 on an earnings per share basis. Icon employs 12,500 workers across the globe.
How can I contact Icon?
Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.
MarketBeat Community Rating for Icon (ICLR)MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Icon (NASDAQ:ICLR) Earnings History and Estimates Chart
Icon (NASDAQ ICLR) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/26/2017||9/30/2017||$1.32||$1.35||$438.09 million||$440.30 million||View||N/A|
|7/27/2017||6/30/2017||$1.30||$1.31||$430.68 million||$431.00 million||View||N/A|
|4/27/2017||3/31/2017||$1.27||$1.29||$432.21 million||$432.00 million||View||N/A|
|2/16/2017||Q416||$1.26||$1.33||$440.78 million||$435.00 million||View||Listen|
|10/20/2016||Q316||$1.18||$1.19||$420.14 million||$420.20 million||View||Listen|
|7/26/2016||Q216||$1.14||$1.14||$409.97 million||$411.00 million||View||Listen|
|4/26/2016||Q116||$1.11||$1.12||$414.35 million||$400.50 million||View||Listen|
|2/23/2016||Q415||$1.10||$1.11||$409.42 million||$403.00 million||View||Listen|
|10/27/2015||Q315||$1.01||$1.02||$399.02 million||$394.70 million||View||Listen|
|7/28/2015||Q215||$0.90||$0.95||$402.15 million||$389.00 million||View||Listen|
|4/28/2015||Q115||$0.81||$0.90||$391.11 million||$388.00 million||View||N/A|
|2/25/2015||Q4||$0.76||$0.87||$391.37 million||$390.10 million||View||N/A|
|10/22/2014||Q314||$0.70||$0.79||$391.12 million||$388.00 million||View||Listen|
|7/30/2014||Q2||$0.58||$0.64||$376.89 million||$376.00 million||View||Listen|
|4/30/2014||Q1||$0.50||$0.57||$352.14 million||$350.00 million||View||Listen|
|2/20/2014||Q413||$0.45||$0.53||$339.86 million||$345.00 million||View||Listen|
|10/24/2013||Q313||$0.41||$0.45||$332.58 million||$339.80 million||View||Listen|
|7/25/2013||Q2 2013||$0.38||$0.43||$321.82 million||$334.20 million||View||Listen|
|4/25/2013||Q1 2013||$0.34||$0.36||$300.81 million||$317.00 million||View||Listen|
|2/19/2013||Q4 2012||$0.33||$0.34||$291.96 million||$300.00 million||View||Listen|
|11/1/2012||Q312||$0.27||$0.29||$282.67 million||$286.00 million||View||N/A|
Icon (NASDAQ:ICLR) Earnings Estimates
2017 EPS Consensus Estimate: $5.29
2018 EPS Consensus Estimate: $5.94
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Icon (NASDAQ:ICLR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Icon (NASDAQ ICLR)
No insider trades for this company have been tracked by MarketBeat.com
Icon (NASDAQ ICLR) News Headlines
Icon (NASDAQ:ICLR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Icon (NASDAQ:ICLR) Income Statement, Balance Sheet and Cash Flow Statement
Icon (NASDAQ ICLR) Stock Chart for Thursday, December, 14, 2017